Does the media prefer RXRX or PROK?

In the previous week, ProKidney had 4 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat ProKidney's score of -0.14 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PROK or BCAX?

In the previous week, ProKidney had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.71 beat ProKidney's score of -0.14 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or PROK?

In the previous week, ProKidney had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 9 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.01 beat ProKidney's score of -0.14 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MAZE or PROK?

In the previous week, ProKidney had 5 more articles in the media than Maze Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.55 beat ProKidney's score of -0.14 indicating that Maze Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VIR or PROK?

In the previous week, ProKidney had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.98 beat ProKidney's score of -0.14 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProKidney (PROK) Competitors

$1.74 +0.01 (+0.58%)

As of 04:00 PM Eastern

Compare

PROK vs. RXRX, BCAX, NTLA, MAZE, and VIR

Should you buy ProKidney stock or one of its competitors? ProKidney's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), Bicara Therapeutics (BCAX), Intellia Therapeutics (NTLA), Maze Therapeutics (MAZE), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProKidney compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Recursion Pharmaceuticals currently has a consensus target price of $8.06, indicating a potential upside of 130.95%. ProKidney has a consensus target price of $12.00, indicating a potential upside of 589.66%. Given ProKidney's stronger consensus rating and higher probable upside, analysts plainly believe ProKidney is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Recursion Pharmaceuticals has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Recursion Pharmaceuticals has a net margin of -945.94% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
ProKidney	-10,288.39%	N/A	-27.39%

ProKidney has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	25.02	-$644.76M	-$1.04	N/A
ProKidney	$890K	591.05	-$68.99M	-$0.55	N/A

In the previous week, ProKidney had 4 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.99 beat ProKidney's score of -0.14 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ProKidney beats Recursion Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does ProKidney compare to Bicara Therapeutics?

ProKidney (NASDAQ:PROK) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Bicara Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Bicara Therapeutics	N/A	-41.49%	-38.59%

ProKidney presently has a consensus price target of $12.00, indicating a potential upside of 589.66%. Bicara Therapeutics has a consensus price target of $32.64, indicating a potential upside of 31.97%. Given ProKidney's higher possible upside, equities analysts clearly believe ProKidney is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

ProKidney has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market.

In the previous week, ProKidney had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.71 beat ProKidney's score of -0.14 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicara Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

51.6% of ProKidney shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ProKidney has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	591.05	-$68.99M	-$0.55	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

ProKidney beats Bicara Therapeutics on 11 of the 16 factors compared between the two stocks.

How does ProKidney compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Intellia Therapeutics currently has a consensus price target of $21.15, indicating a potential upside of 60.37%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 589.66%. Given ProKidney's stronger consensus rating and higher probable upside, analysts clearly believe ProKidney is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Intellia Therapeutics has a net margin of -672.16% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
ProKidney	-10,288.39%	N/A	-27.39%

Intellia Therapeutics has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

In the previous week, ProKidney had 2 more articles in the media than Intellia Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 9 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.01 beat ProKidney's score of -0.14 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ProKidney has lower revenue, but higher earnings than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	27.31	-$412.69M	-$3.36	N/A
ProKidney	$890K	591.05	-$68.99M	-$0.55	N/A

Summary

ProKidney beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Maze Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
ProKidney	-10,288.39%	N/A	-27.39%

In the previous week, ProKidney had 5 more articles in the media than Maze Therapeutics. MarketBeat recorded 11 mentions for ProKidney and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.55 beat ProKidney's score of -0.14 indicating that Maze Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

ProKidney has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.81	-$131.12M	-$2.52	N/A
ProKidney	$890K	591.05	-$68.99M	-$0.55	N/A

Maze Therapeutics currently has a consensus target price of $66.00, suggesting a potential upside of 123.12%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 589.66%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

51.6% of ProKidney shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ProKidney beats Maze Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ProKidney compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and ProKidney (NASDAQ:PROK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ProKidney has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	27.35	-$437.99M	-$1.86	N/A
ProKidney	$890K	591.05	-$68.99M	-$0.55	N/A

Vir Biotechnology currently has a consensus target price of $20.63, suggesting a potential upside of 86.15%. ProKidney has a consensus target price of $12.00, suggesting a potential upside of 589.66%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Vir Biotechnology has a net margin of -638.88% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
ProKidney	-10,288.39%	N/A	-27.39%

In the previous week, ProKidney had 4 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for ProKidney and 7 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.98 beat ProKidney's score of -0.14 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vir Biotechnology has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Summary

ProKidney beats Vir Biotechnology on 8 of the 15 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$526.04M	$4.03B	$7.29B	$12.77B
Dividend Yield	N/A	3.63%	2.54%	10.79%
P/E Ratio	-3.16	11.48	272.76	24.14
Price / Sales	591.05	1,366.69	626.72	98.11
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	-0.60	16.88	13.14	6.23
Net Income	-$68.99M	-$22.76M	$3.47B	$348.07M
7 Day Performance	17.57%	1.55%	1.38%	0.67%
1 Month Performance	16.00%	11.70%	8.62%	4.84%
1 Year Performance	-26.89%	56.88%	25.90%	16.83%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.776 of 5 stars	$1.74 +0.6%	$12.00 +589.7%	-26.4%	$523.02M	$890K	N/A	3
RXRX Recursion Pharmaceuticals	2.0717 of 5 stars	$3.50 +13.3%	$8.06 +130.3%	-26.3%	$1.65B	$74.68M	N/A	400	Options Volume High Trading Volume
BCAX Bicara Therapeutics	2.1689 of 5 stars	$25.86 +3.8%	$32.64 +26.2%	+117.1%	$1.65B	N/A	N/A	32
NTLA Intellia Therapeutics	3.0448 of 5 stars	$13.28 +14.5%	$21.15 +59.3%	+18.7%	$1.63B	$67.67M	N/A	600	Positive News Analyst Forecast
MAZE Maze Therapeutics	2.5368 of 5 stars	$29.75 +2.1%	$66.00 +121.8%	+128.5%	$1.62B	$167.50M	N/A	121	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. RXRX, BCAX, NTLA, MAZE, and VIR

How does ProKidney compare to Recursion Pharmaceuticals?

Summary

How does ProKidney compare to Bicara Therapeutics?

Summary

How does ProKidney compare to Intellia Therapeutics?

Summary

How does ProKidney compare to Maze Therapeutics?

Summary

How does ProKidney compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. RXRX, BCAX, NTLA, MAZE, and VIR

How does ProKidney compare to Recursion Pharmaceuticals?

Do analysts prefer RXRX or PROK?

Which has more risk and volatility, RXRX or PROK?

Is RXRX or PROK more profitable?

Which has preferable earnings and valuation, RXRX or PROK?

Does the media prefer RXRX or PROK?

Do institutionals and insiders have more ownership in RXRX or PROK?

Summary

How does ProKidney compare to Bicara Therapeutics?

Is PROK or BCAX more profitable?

Do analysts prefer PROK or BCAX?

Which has more risk & volatility, PROK or BCAX?

Does the media refer more to PROK or BCAX?

Do institutionals & insiders believe in PROK or BCAX?

Which has preferable earnings and valuation, PROK or BCAX?

Summary

How does ProKidney compare to Intellia Therapeutics?

Do analysts recommend NTLA or PROK?

Is NTLA or PROK more profitable?

Which has more risk & volatility, NTLA or PROK?

Does the media prefer NTLA or PROK?

Do insiders and institutionals believe in NTLA or PROK?

Which has higher valuation and earnings, NTLA or PROK?

Summary

How does ProKidney compare to Maze Therapeutics?

Is MAZE or PROK more profitable?

Does the media prefer MAZE or PROK?

Which has more risk and volatility, MAZE or PROK?

Which has stronger valuation and earnings, MAZE or PROK?

Do analysts recommend MAZE or PROK?

Do insiders & institutionals hold more shares of MAZE or PROK?

Summary

How does ProKidney compare to Vir Biotechnology?

Do institutionals & insiders have more ownership in VIR or PROK?

Which has better valuation and earnings, VIR or PROK?

Do analysts rate VIR or PROK?

Is VIR or PROK more profitable?

Does the media prefer VIR or PROK?

Which has more volatility and risk, VIR or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools